U.S. Probes Resuming Painkiller Trials Tied to Joint Failure
This article is for subscribers only.
U.S. regulators asked an advisory panel whether Pfizer Inc. and Johnson & Johnson, the two biggest U.S. makers of health-care products, should resume human trials on a class of experimental painkillers linked to joint failure.
Studies on the class of drugs known as anti-nerve growth factor drugs, designed to treat osteoarthritis and chronic back pain, were halted in 2010 after the joint problems were reported. All trials are stopped except those in cancer pain.